ArticleInternational journal of surgical oncology2012
Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II Trial.
Article in International journal of surgical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Optimizing surgical and imatinib therapy for the treatment of gastrointestinal stromal tumors.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2013Pooled it
- Pretreatment Tumor DNA Sequencing of KIT and PDGFRA in Endosonography-Guided Biopsies Optimizes the Preoperative Management of Gastrointestinal Stromal Tumors.Molecular diagnosis & therapy · 2020Trial
- Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach.British journal of cancer · 2017Trial
- Long-Term Outcomes After Multiorgan Resection of Primary Gastrointestinal Stromal Tumors.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2026Article
- Challenge of gastro-intestinal stromal tumor management in low-income countries: example of Benin.World journal of surgical oncology · 2022Article
- Review
- Current treatment strategies and future perspectives for gastrointestinal stromal tumors.World journal of gastrointestinal pathophysiology · 2022Review
- A Retrospective Study of Postoperative Outcomes in 98 Patients Diagnosed with Gastrointestinal Stromal Tumor (GIST) of the Upper, Middle, and Lower Gastrointestinal Tract Between 2009 and 2019 at a Single Center in Poland.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- Prognostic Factors After Neoadjuvant Imatinib for Newly Diagnosed Primary Gastrointestinal Stromal Tumor.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2021Article
- Rectovaginal extragastrointestinal stromal tumour (EGIST): an additional entity to be considered in the differential diagnosis of tumours of the rectovaginal septum.BMJ case reports · 2021Review
- Development of a Malignancy Potential Binary Prediction Model Based on Deep Learning for the Mitotic Count of Local Primary Gastrointestinal Stromal Tumors.Korean journal of radiology · 2021Article
- Neoadjuvant Therapy to Downstage the Extent of Resection of Gastrointestinal Stromal Tumors.Visceral medicine · 2018Review
- Neoadjuvant therapy for gastrointestinal stromal tumor.Translational gastroenterology and hepatology · 2018Review
- Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT).BMC cancer · 2017Article
- Rectal GIST-Outcomes and viewpoint from a tertiary cancer center.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2016Article
- Preoperative imatinib facilitates complete resection of locally advanced primary GIST by a less invasive procedure.Medical oncology (Northwood, London, England) · 2014Article
- Targeted therapy for cancer: the gastrointestinal stromal tumor model.Surgical oncology clinics of North America · 2013Review
- Surgical treatment of gastric gastrointestinal stromal tumor.Journal of gastric cancer · 2013Article
- Update on imatinib for gastrointestinal stromal tumors: duration of treatment.OncoTargets and therapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose. Proven efficacy of imatinib mesylate in gastrointestinal stromal tumour (GIST) has led to its use in advanced disease and, more recently, in adjuvant and neoadjuvant settings. The purpose of this study was to evaluate the optimal neoadjuvant imatinib duration to reduce the morbidity of surgery and increase the possibility of resection completeness in advanced tumours. Patients and Method. Patients with advanced GIST were enrolled into a registered open-label multicenter trial and received imatinib daily for a maximum of 12 months, followed by en bloc resection. Data were prospectively collected regarding tumour assessment, response rate, surgical characteristics, recurrence, and survival. Results. Fourteen patients with advanced GIST were enrolled. According to RECIST criteria, 6 patients had partial response and 8 had stable disease. The overall tumour size reduction was 25% (0-62.5%), and there was no tumour progression. Eleven patients underwent tumour resection, and all had R0 resection. After a median followup of 48 months, 4-year OS and DFS were 100% and 64%, respectively. Conclusion. This prospective trial showed that one year of neoadjuvant imatinib in advanced GIST is safe and associated with high rate of complete microscopic resection. It is not associated with increased resistance, progression, or complication rates.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.